Mometasone
- Generic Name
- Mometasone
- Brand Names
- Asmanex, Dulera, Elocom, Elocon, Nasonex, Ryaltris, Sinuva, Zenhale
- Drug Type
- Small Molecule
- Chemical Formula
- C27H30Cl2O6
- CAS Number
- 83919-23-7
- Unique Ingredient Identifier
- 04201GDN4R
- Background
Mometasone furoate is a corticosteroid drug that can be used for the treatment of asthma, rhinitis, and certain skin conditions. It has a glucocorticoid receptor binding affinity 22 times stronger than dexamethasone and higher than many other corticosteroids as well. Mometasone furoate is formulated as a dry powder inhaler, nasal spray, and ointment for its ...
- Indication
Inhaled mometasone furoate is indicated for prophylaxis of asthma in patients ≥4 years. Applied topically as an ointment, mometasone furoate is indicated for symptomatic treatment of dermatitis and pruritis in patients ≥2 years.
...
- Associated Conditions
- Asthma, Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Dermatitis, Dermatitis, Eczematous caused by superficial Fungal skin infection, Moderate to Severe Plaque Psoriasis, Pruritus, Psoriasis, Psoriasis, Moderate to Severe, Seasonal Allergic Rhinitis, Seasonal Allergies, Skin Diseases, Eczematous, Skin Infections, Moderate, severe Seasonal Allergic Rhinitis, Ocular effects
- Associated Therapies
- -
A Clinical Trial About Treatment of Mild to Moderate Persistent Alergic Rhinnitis With Test or Reference Mometasone (PUMA)
- Conditions
- Interventions
- First Posted Date
- 2011-06-14
- Last Posted Date
- 2017-09-18
- Lead Sponsor
- Eurofarma Laboratorios S.A.
- Target Recruit Count
- 364
- Registration Number
- NCT01372865
- Locations
- 🇧🇷
IMA Brasil - Instituto de Pesquisa Clínica e Medicina Avançada, Sao Paulo, Brazil
Acute and Chronic Effects of Inhaled Steroids on Pulmonary Function in Persons With Spinal Cord Injury
- First Posted Date
- 2011-05-13
- Last Posted Date
- 2015-10-23
- Lead Sponsor
- James J. Peters Veterans Affairs Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT01353599
- Locations
- 🇺🇸
Kessler Institute for Rehabilitation, West Orange, New Jersey, United States
🇺🇸James J. Peters VA Medical Center, Bronx, New York, United States
Comparison of Efficacy and Safety of 0.1% Tacrolimus and 0.1% Mometasone Furoate for Adult Vitiligo
- First Posted Date
- 2011-04-12
- Last Posted Date
- 2012-10-10
- Lead Sponsor
- Mahidol University
- Target Recruit Count
- 30
- Registration Number
- NCT01333410
- Locations
- 🇹🇭
Department of Dermatology, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand
Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate
- Conditions
- Interventions
- First Posted Date
- 2010-10-26
- Last Posted Date
- 2022-11-03
- Lead Sponsor
- Azidus Brasil
- Target Recruit Count
- 40
- Registration Number
- NCT01228656
A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures
- Conditions
- Interventions
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2017-08-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 540
- Registration Number
- NCT01199757
A Study of Long-term Administration of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06333AM1)
- First Posted Date
- 2010-07-19
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 80
- Registration Number
- NCT01165424
Multicenter, Double-blind, Randomized, Placebo-controlled Study of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06332)
- Conditions
- Interventions
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 333
- Registration Number
- NCT01135134
Nasonex® Nasal Suspension 50 μg Long-term Designated Drug Use Investigation (Study P05876)
- First Posted Date
- 2009-05-18
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 3806
- Registration Number
- NCT00903721
Assessment of Intranasal Steroids in Allergic Rhinitis When Used Alone or in Combination With an Oral Antihistamine (Study P03270)
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 72
- Registration Number
- NCT00834119
A Study to Compare the Efficacy of QAV680 Against Placebo in Treating Seasonal Allergic Rhinitis in an Environmental Exposure Chamber
- Conditions
- Interventions
- First Posted Date
- 2008-11-04
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 44
- Registration Number
- NCT00784732
- Locations
- 🇨🇦
Novartis Investigator Site, Toronto, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.